— Know what they know.
Not Investment Advice

GLUE NASDAQ

Monte Rosa Therapeutics, Inc.
1W: -6.2% 1M: -9.0% 3M: -50.6% YTD: -30.4% 1Y: -4.3% 3Y: +289.1% 5Y: -52.8%
$10.66
+0.18 (+1.72%)
 
Weekly Expected Move ±9.1%
$9 $10 $11 $12 $13
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 33 · $909.4M mcap · 60M float · 2.42% daily turnover · Short 55% of daily vol
Credit Risk of going bust: higher than 56% of companies Debt: 4.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.3%), Monte Rosa Therapeutics, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $909.4M.
Distance to default 4.57 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $21.3M (short-term plus half of long-term), stock volatility 78.8%; Altman Z'' 3.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$909.4M
52W Range9.68-25.77
Volume1,457,929
Avg Volume1,453,451
Beta1.37
Dividend—
Analyst Ratings
8 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOMarkus Warmuth
Employees173
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-24
321 Harrison Avenue
Boston, MA 02118
US
617 949 2643
About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Bowen Matthew S-Sale 13 $10.56 2026-10-05
Warmuth Markus S-Sale 9,500 $23.18 2026-07-16
Champoux Jennifer S-Sale 4,351 $23.38 2026-07-15
Townson Sharon M-Exempt 6,000 $6.14 2026-07-06
Townson Sharon S-Sale 5,600 $23.25 2026-07-06

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms